Takara L Stanley et al found that the injectable synthetic growth-hormone-releasing hormone, tesamorelin, reduces liver fat and prevents liver fibrosis (scarring) in people living with HIV.
About 43% of the enrolled participants had at least mild fibrosis, and 33% had a more severe subset of non-alcoholic fatty liver disease (NAFLD) called non-alcoholic steatohepatitis (NASH). Participants were randomly assigned to two cohorts to receive either 2 mg tesamorelin once daily or placebo once daily for 12 months. This was followed by a 6-month open-label phase during which all participants received tesamorelin 2 mg daily. After one year, 35 percent of study participants who received tesamorelin achieved a normal hepatic fat fraction (HFF), while only 4% of those on placebo reached that range with nutritional advice alone. Overall, tesamorelin was well-tolerated and reduced participants’ HFF by an absolute difference of 4.1%.
Source: The Lancet HIV October 11, 2019, DOI: https://doi.org/10.1016/S2352-3018(19)30338-8